Medivation Inc (MDVN)

81.42
0.00 (0.00)
NASDAQ : Health Care
Prev Close 81.42
Open 81.42
Day Low/High 81.42 / 81.45
52 Wk Low/High 26.41 / 63.34
Volume 2.81M
Avg Volume 4.05M
Exchange NASDAQ
Shares Outstanding 165.93M
Market Cap 13.45B
EPS 1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation

Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition Of Medivation

Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer's pending acquisition of Medivation, Inc.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of Medivation, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces An Investigation Of The Board Of Directors Of Medivation, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc.

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.

Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street

Jim Cramer's 'Mad Money' Recap: The Urge to Merge Rules Wall Street

There are too many companies in just about every sector of this market, Cramer says.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. For $81.50 Per Share Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. For $81.50 Per Share Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Medivation, Inc.

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.

Why Pfizer's Latest Deal Could Send Its Shares Soaring

Why Pfizer's Latest Deal Could Send Its Shares Soaring

The acquisition of Medivation gives the pharma giant a top-selling oncology drug and an immediate profit boost.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Pfizer buys antibiotics business from AstraZeneca; Tesla unveils Model S version that can go 300 miles on a single charge; U.S. stock futures rise slightly.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. To Pfizer Inc. Is Fair To Shareholders

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Whether The Sale Of Medivation, Inc. To Pfizer Inc. Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Medivation, Inc.

Medivation (MDVN) Stock Downgraded After Pfizer Deal

Medivation (MDVN) Stock Downgraded After Pfizer Deal

Medivation's (MDVN) stock rating was cut by several firms on Tuesday morning after the company agreed to be acquired by Pfizer (PFE) for $14 billion yesterday.

Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week

Jim Cramer's 'Mad Money' Recap: I'm Watching Best Buy, PVH, Yellen This Week

Earnings season is far from over, Cramer says, and the Fed chief gives a major speech Friday.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...

Market Keeps Chasing Its Own Tail

Stocks travel a good distance just to end up nowhere.

Stocks Waver as Investors Wait for Fed Clarity

Stocks Waver as Investors Wait for Fed Clarity

Wall Street will get more clues on the Fed's rate hike plans later this week, but uncertainty over what they might be led to jittery trading on Monday.

Stocks Struggle for Direction as Jackson Hole Conference Looms

Stocks Struggle for Direction as Jackson Hole Conference Looms

Stocks fluctuate Monday afternoon as a selloff in crude oil hits the energy sector and Federal Reserve speeches at the end of the week leave investors wary.

Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer Inc.

Medivation, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Merger With Pfizer Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Medivation, Inc.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Cramer: A Bunch of Semis Are Ripe for the Picking

Cramer: A Bunch of Semis Are Ripe for the Picking

That's the hot spot in M&A right now.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

Pfizer to Pick Up Medivation in All-Cash Deal

PFE is trading up on the announcement, and the deal should add to earnings in 2017.